These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 38068538)
61. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Mehran R; Baber U; Steg PG; Ariti C; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Berger PB; Iakovou I; Dangas G; Waksman R; Antoniucci D; Sartori S; Krucoff MW; Hermiller JB; Shawl F; Gibson CM; Chieffo A; Alu M; Moliterno DJ; Colombo A; Pocock S Lancet; 2013 Nov; 382(9906):1714-22. PubMed ID: 24004642 [TBL] [Abstract][Full Text] [Related]
62. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. Serruys PW; Takahashi K; Chichareon P; Kogame N; Tomaniak M; Modolo R; Chang CC; Komiyama H; Soliman O; Wykrzykowska JJ; de Winter RJ; Ferrario M; Dominici M; Buszman P; Bolognese L; Tumscitz C; Benit E; Stoll HP; Hamm C; Steg PG; Onuma Y; Jüni P; Windecker S; Vranckx P; Colombo A; Valgimigli M Eur Heart J; 2019 Aug; 40(31):2595-2604. PubMed ID: 31397487 [TBL] [Abstract][Full Text] [Related]
63. Prediction-Determining Outcomes and Their Predictors in Atrial Fibrillation Patients Receiving Multicomponent Antithrombotic Therapy in Real Clinical Practice. Krivosheeva EN; Panchenko EP; Kropacheva ES; Dobrovolsky AB; Titaeva EV; Mironov VM; Samko AN Kardiologiia; 2020 Sep; 60(8):33-45. PubMed ID: 33155957 [TBL] [Abstract][Full Text] [Related]
64. Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study. Park J; Choi EK; Han KD; Choi YJ; Lee E; Choe W; Lee SR; Cha MJ; Lim WH; Kang J; Park KW; Oh S; Lip GYH PLoS One; 2019; 14(1):e0209593. PubMed ID: 30645601 [TBL] [Abstract][Full Text] [Related]
65. Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients. Kim DY; Cho SW; Park KT; Ahn JH; Park TK; Jang YH; Choi KH; Lee JM; Yang JH; Song YB; Choi JH; Choi SH; Gwon HC; Lee SH; Hahn JY J Korean Med Sci; 2021 Apr; 36(16):e106. PubMed ID: 33904262 [TBL] [Abstract][Full Text] [Related]
66. Risk of recurrent stroke in patients with atrial fibrillation treated with oral anticoagulants alone or in combination with anti-platelet therapy. RAF and RENO-EXTEND Investigators* Eur Stroke J; 2023 Sep; 8(3):722-730. PubMed ID: 37458099 [TBL] [Abstract][Full Text] [Related]
67. Safety and efficacy of anticoagulant monotherapy in atrial fibrillation and stable coronary artery disease: A systematic review and meta-analysis. Ullah W; Sattar Y; Shaukat M; Fischman DL Eur J Intern Med; 2020 Nov; 81():54-59. PubMed ID: 32709546 [TBL] [Abstract][Full Text] [Related]
68. Direct Oral Anticoagulants Affect Activated Clotting Time During and Bleeding Events After Percutaneous Coronary Intervention. Shibahashi E; Abe T; Kamishima K; Ebihara S; Moriyama T; Shimazaki K; Saito K; Uchigata Y; Jujo K Am J Cardiol; 2023 Oct; 204():1-8. PubMed ID: 37531715 [TBL] [Abstract][Full Text] [Related]
69. The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Fanaroff AC; Lopes RD Prog Cardiovasc Dis; 2021; 69():11-17. PubMed ID: 34883097 [TBL] [Abstract][Full Text] [Related]
70. Optimisation of oral anticoagulants for patients with atrial fibrillation within 12 months after percutaneous coronary intervention: A Wang S; Liu Y; Wang L; Zuo H; Tian Y; Wang Y; Yin D; Zhang H; Tian Y Int J Cardiol Heart Vasc; 2021 Oct; 36():100850. PubMed ID: 34401468 [TBL] [Abstract][Full Text] [Related]
72. Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention. Kitahara H; Tateishi K; Shiko Y; Inaba Y; Kobayashi Y; Inoue T PLoS One; 2022; 17(7):e0272140. PubMed ID: 35901007 [TBL] [Abstract][Full Text] [Related]
73. P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis. Feng WH; Chang YC; Lin YH; Chen HL; Chen CY; Lin TH; Lin TC; Chang CT; Kuo HF; Chang HM; Chu CS Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259380 [TBL] [Abstract][Full Text] [Related]
74. Relationship between predicting bleeding complication in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score and mortality among patients with atrial fibrillation undergoing percutaneous coronary intervention. Asif A; Sezer A; Thoma F; Toma C; Schindler J; Fowler J; Smith C; Marroquin OC; Mulukutla SR Catheter Cardiovasc Interv; 2021 Nov; 98(5):838-845. PubMed ID: 33300267 [TBL] [Abstract][Full Text] [Related]
75. Short-term direct oral anticoagulation or dual antiplatelet therapy following left atrial appendage closure in patients with relative contraindications to chronic anticoagulation therapy. Faroux L; Cruz-González I; Arzamendi D; Freixa X; Nombela-Franco L; Peral V; Caneiro-Queija B; Mangieri A; Trejo-Velasco B; Asmarats L; Regueiro A; McInerney A; Mas-Lladó C; Estevez-Loureiro R; Laricchia A; O'Hara G; Rodés-Cabau J Int J Cardiol; 2021 Jun; 333():77-82. PubMed ID: 33647365 [TBL] [Abstract][Full Text] [Related]
76. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. Watanabe H; Morimoto T; Natsuaki M; Yamamoto K; Obayashi Y; Ogita M; Suwa S; Isawa T; Domei T; Yamaji K; Tatsushima S; Watanabe H; Ohya M; Tokuyama H; Tada T; Sakamoto H; Mori H; Suzuki H; Nishikura T; Wakabayashi K; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Morino Y; Kadota K; Furukawa Y; Nakagawa Y; Kimura T; JAMA Cardiol; 2022 Apr; 7(4):407-417. PubMed ID: 35234821 [TBL] [Abstract][Full Text] [Related]
77. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160 [TBL] [Abstract][Full Text] [Related]
78. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting. Lacoste JL; Hansen CL Am J Health Syst Pharm; 2019 Sep; 76(18):1395-1402. PubMed ID: 31505555 [TBL] [Abstract][Full Text] [Related]